| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Preventive Medicine and Environmental Health [J. R. C., A. S. P., S. D. P., B. C-H. C., C. F. L., J. C. T.] and Pathology and Urology [M. B. C.], The University of Iowa College of Medicine, Iowa City, Iowa 52242, and Occupational Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892 [K. P. C.]
A family history of prostate cancer has been associated with prostate cancer risk in most prior studies, and more limited data suggest that a family history of breast cancer may also be important; however, there are no data from a population-based cohort study of prostate cancer incidence that adjusts for major confounders. We conducted follow-up through 1995 on 1557 men, ages 4086 years, who were randomly selected (81% response rate) as cancer-free controls for a population-based case-control study conducted in Iowa from 19871989. Family history of cancer in parents and siblings was obtained using a mailed questionnaire. Incident cancers and deaths were ascertained through linkages to state and national databases; 101 incident cases of prostate cancer were identified. At baseline, 4.6% of the cohort reported a family history of prostate cancer in a brother or father, and this was positively associated with prostate cancer risk after adjustment for age [relative risk (RR) = 3.2; 95% confidence interval (CI), 1.85.7] or after multivariate adjustment for age, alcohol, and dietary factors (RR = 3.7; 95% CI, 1.97.2). Risk was greater if a brother had prostate cancer (RR = 4.5; 95% CI, 2.19.7) than if a father had prostate cancer (RR = 2.3; 95% CI, 1.05.3). Also at baseline, 9.6% of the cohort had a family history of breast and/or ovarian cancer in a mother or sister, and this was positively associated with prostate cancer risk (age-adjusted RR = 1.7; 95% CI, 1.03.0; multivariate RR = 1.7; 95% CI, 0.93.2). Men with a family history of both prostate and breast/ovarian cancer were also at increased risk of prostate cancer (RR = 5.8; 95% CI, 2.414). There was no association with a family history of colon cancer. Exclusion of well-differentiated, localized tumors did not alter these findings. These data from an incidence study confirm that a family history of prostate cancer is a strong prostate cancer risk factor after adjustment for dietary and other risk factors, and suggest that selection and recall bias have not had an important influence on most case-control study results. These data also support the idea that a family history of breast cancer may also be a prostate cancer risk factor.
This article has been cited by other articles:
![]() |
Y.-C. Chen, P. Kraft, P. Bretsky, S. Ketkar, D. J. Hunter, D. Albanes, D. Altshuler, G. Andriole, C. D. Berg, H. Boeing, et al. Sequence Variants of Estrogen Receptor {beta} and Risk of Prostate Cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1973 - 1981. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Chen, E. Giovannucci, P. Kraft, R. Lazarus, and D. J. Hunter Association between Toll-Like Receptor Gene Cluster (TLR6, TLR1, and TLR10) and Prostate Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1982 - 1989. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nagata, T. Sonoda, M. Mori, N. Miyanaga, K. Okumura, K. Goto, S. Naito, K. Fujimoto, Y. Hirao, A. Takahashi, et al. Dietary Isoflavones May Protect against Prostate Cancer in Japanese Men J. Nutr., August 1, 2007; 137(8): 1974 - 1979. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Chen, E. Giovannucci, R. Lazarus, P. Kraft, S. Ketkar, and D. J. Hunter Sequence Variants of Toll-Like Receptor 4 and Susceptibility to Prostate Cancer Cancer Res., December 15, 2005; 65(24): 11771 - 11778. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Murff, D. R. Spigel, and S. Syngal Does This Patient Have a Family History of Cancer?: An Evidence-Based Analysis of the Accuracy of Family Cancer History JAMA, September 22, 2004; 292(12): 1480 - 1489. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-H. Tung, M. T. Goodman, A. H. Wu, K. McDuffie, L. R. Wilkens, A. M. Y. Nomura, and L. N. Kolonel Aggregation of Ovarian Cancer with Breast, Ovarian, Colorectal, and Prostate Cancer in First-degree Relatives Am. J. Epidemiol., April 15, 2004; 159(8): 750 - 758. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Schaid The complex genetic epidemiology of prostate cancer Hum. Mol. Genet., April 1, 2004; 13(90001): R103 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Stanford, L. P. Sabacan, E. A. Noonan, L. Iwasaki, J. Shu, Z. Feng, and E. A. Ostrander Association of HPC2/ELAC2 Polymorphisms with Risk of Prostate Cancer in a Population-based Study Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 876 - 881. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Lange, H. Chen, K. Brierley, E. E. Perrone, C. H. Bock, E. Gillanders, M. E. Ray, and K. A. Cooney Linkage Analysis of 153 Prostate Cancer Families Over a 30-cM Region Containing the Putative Susceptibility Locus HPCX Clin. Cancer Res., December 1, 1999; 5(12): 4013 - 4020. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |